{"url":"https://newsforagent.com/news/2026-11-06/brii-biosciences-enrich-hbsag-loss","markdown_url":"https://newsforagent.com/news/2026-11-06/brii-biosciences-enrich-hbsag-loss.md","title":"Brii Biosciences Reports 32.4% HBsAg Loss at 24 Weeks","headline":"Brii Biosciences ENRICH Data Show 32.4% Retaining HBsAg Loss at 24 Weeks","description":"Brii Biosciences reported 32.4% of Phase 2b ENRICH patients kept HBsAg loss 24 weeks after treatment, with 41.9% achieving loss at treatment end.","section":"Research & Clinical Trials","published_at":"2026-11-06T01:00:19+00:00","modified_at":"2026-11-06T01:00:19+00:00","author":"News Desk","key_takeaways":["In Phase 2b ENRICH, 41.9% of patients achieved HBsAg loss at end of treatment and 32.4% maintained it 24 weeks later.","ENHANCE Part A1 triple therapy reached 25.5% HBsAg loss at treatment end versus 10.2% with PEG-IFNα monotherapy, with no statistical significance given.","Brii Biosciences reported a US$276.1 million cash position as of December 31, 2025."],"companies":[{"name":"Brii Biosciences","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000pod/brii-biosciences","website":"https://www.briibio.com"}],"source":{"publisher":"TradingView","title":"Brii Biosciences Limited Reports 32.4% HBsAg Loss at 24 Weeks in ENRICH","url":"https://www.tradingview.com/news/tradingview:d620f9c16a1c6:0-brii-biosciences-limited-reports-32-4-hbsag-loss-at-24-weeks-in-enrich/"},"other_sources":[],"tags":["Research & Clinical Trials","Brii Biosciences"],"body_markdown":"Brii Biosciences reported that 32.4% of patients in its Phase 2b ENRICH study retained HBsAg loss 24 weeks after treatment ended, with 41.9% achieving loss at the end of treatment. [TradingView](https://www.tradingview.com/news/tradingview:d620f9c16a1c6:0-brii-biosciences-limited-reports-32-4-hbsag-loss-at-24-weeks-in-enrich/) published the results on November 6, 2026. [Brii Biosciences](https://akta.pro/company-profiles/0000pod/brii-biosciences) is a clinical-stage biopharmaceutical company developing therapies for infectious diseases, chiefly chronic hepatitis B, and central nervous system disorders.\n\n## Inside the ENRICH and ENHANCE Results\n\nThe ENRICH figures describe an end-of-treatment response rather than a long-term cure rate, and the release reports consistency with ENSURE Cohort 4. In ENHANCE Part A1, triple therapy produced 25.5% HBsAg loss at treatment end against 10.2% for PEG-IFNα monotherapy, and 17.3% against 6.1% at 24 weeks. The release gives no statistical significance for either comparison.\n\nENHANCE Part A2 recorded 22.5% HBsAg loss at treatment end for the priming regimen. Brii Biosciences said the regimens were generally safe and well tolerated, without adverse-event rates or detailed safety data. The company described the Phase 2b data as adding to earlier Phase 2 studies.\n\n## Brii Biosciences' Cash and Funding Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Brii Biosciences held a US$276.1 million cash position as of December 31, 2025. The same records list a $260 million Series A/B round at its founding in 2018 and a $155 million Series C completed in March 2021, for total funding of $415 million.\n\n## Earlier Hepatitis B Readouts\n\nIn July 2026, Investing.com reported mixed end-of-treatment results from two Phase 2b studies, with ENRICH showing HBsAg loss rates of 42.9% and 40.0% against ENHANCE's 25.5%. In May 2026, BioSpace reported that Brii Bio presented final Phase 2 ENSURE results at EASL Congress 2026, showing elebsiran plus PEG-IFNα achieved higher functional cure rates than PEG-IFNα alone. In August 2026, AInvest reported that Brii Biosciences extended its cash runway to 2029 by cutting research and administrative expenses while reporting mixed Phase 2b results for BRII-179.\n\n## What Comes After the ENRICH Readout\n\nThe release states that further trials would be needed to confirm durable HBsAg loss and to assess safety and efficacy across the regimens.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}